Opthea Limited (ASX: OPT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Opthea Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Opthea Limited (ASX: OPT)
Latest News
Share Fallers
Why Afterpay, Atomo, Opthea, & Sealink shares are falling today
Small Cap Shares
4 small cap ASX shares to watch
Share Fallers
Why Nanosonics, Oil Search, Opthea, & Piedmont Lithium are tumbling
Share Market News
Why Bigtincan, Oil Search, Opthea, & Xref shares are racing higher
Healthcare Shares
Here's why the Opthea (ASX:OPT) share price is soaring 8%
Share Gainers
Why Bigtincan, Opthea, Seven West Media, & Telix shares are charging higher
Share Gainers
Why the Opthea (ASX:OPT) share price is rocketing 12% higher
Healthcare Shares
The ASX healthcare shares Goldman Sachs rates as a buy
Share Gainers
Why Aristocrat Leisure, Opthea, PointsBet, & Spirit are storming higher:
Share Market News
The Opthea (ASX:OPT) share price up after receiving FDA approval
Share Gainers
Why Codan, Evolution, Opthea, & People Infrastructure shares are charging higher
Share Market News
Why the Opthea (ASX:OPT) share price is soaring 11% today
Frequently Asked Questions
-
No, Opthea does not pay shareholder dividends at this time.
-
Opthea Limited listed on the ASX on 18 April 1991.
OPT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Opthea Limited
Opthea Limited (ASX: OPT) is a biopharmaceutical company specialising in the development of biological therapeutics for retinal eye diseases. The company is developing a novel therapy, OPT-302, designed to be used in combination with existing therapies. OPT-302, the company's leading drug candidate, has the potential to address wet age-related macular degeneration (AMD) and diabetic macular edema (DME) in patients. It is currently at Phase 3 clinical trial stage.
